101 
Market Cap
Stock Chart
ImpediMed - 30 Day Poll
Recent BLOGS About ImpediMed Add New
Latest Company News
|
Impedimed Limited Subsidiary Announces US Civil Action By Former Employee
Reuters Key Development - Dec 14, 2009 |
|
More kudos for ImpediMed BIS device for early detection of lymphedema
Proactive Investors UK - Nov 24, 2009 A University of Sydney study has found that ImpediMed's (ASX: IPD) Bioimpedance Spectroscopy (BIS) device is the most suitable for early detection and monitoring of lymphedema. The share price of ...
|
|
ImpediMed L-Dex® technology for breast cancer, CPT code filed with American Medical Assoc.
Proactive Investors Australia - Nov 12, 2009 Queensland-based ImpediMed (ASX: IPD) announced today that an application for a Category 1 Current Procedural Terminology (CPT) Code has been filed with the American Medical Association. A ...
|
Website
Videos related to ImpediMed
Company Profile
ImpediMed is a company engaged in the development, manufacture and sale of bio-impedance instruments to direct customers and distributors. The devices are applied to: monitoring of secondary lymphedema, general health assessment and weight management, muscle wasting, drug dosing and monitoring and sports medicine and fitness.
The Company operates in two segments:
1. Medical, which is a supplier of non-invasive medical devices to two under-served markets, such as the assessment of individuals at risk of secondary lymphoedema and the monitoring of body composition and hydration
2. Test & Measurement, which is a supplier of power precision testing and measuring equipment.
Revenue: Approx. $3.2 million as of 30th June 2009 for th year.
Cash: Approx. $6.6 million as of 30th June 2009